Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNM-201
- Development stage
- Preclinical
- Lead developer
- Precision NeuroMed
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
PNM-201 is a targeted cytotoxin (immunotoxin) being developed by Precision NeuroMed for the treatment of glioblastoma (GBM). It consists of a recombinant fusion protein combining human interleukin-13 (IL13) with a truncated version of Pseudomonas exotoxin A (PE38). The drug specifically targets glioblastoma tumor stem cells (TSCs) that overexpress the IL13Ra2 receptor, which is minimally expressed in normal brain tissue. Upon binding to IL13Ra2, the fusion toxin is internalized, and the PE38 payload inhibits protein synthesis, leading to cell death. Precision NeuroMed has partnered with Brainlab to utilize precision drug delivery technologies for administration. The program received FDA Orphan Drug Designation in 2025 and is currently in the preclinical stage.
- Other names
- IL13-PE38IL-13-PE38IL 13-PE38IL13-PE38 fusion toxinIL-13-PE38 fusion toxinIL 13-PE38 fusion toxin
02
Targets
IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on PNM-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNM-201.